Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the identification, development and commercialization of pharmaceutical products. The Company markets two products: Xyrem (sodium oxybate), which is a product approved by the United States Food and Drug Administration (FDA), for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy, and Luvox CR (fluvoxamine maleate) marketed for the treatment of obsessive compulsive disorder. Its product candidates are JZP-6 (sodium oxybate) for the treatment of fibromyalgia, JZP-8 (intranasal clonazepam) for the treatment of acute repetitive seizures in epilepsy, and solid oral dosage forms of sodium oxybate.

Jazz (JAZZ) currently has a BUY Signal.
Market Trend Signal™ trend following stocks trading system
Jesse Webb
Market Trend Signal™
Trend Following Stocks – Trade Signals – Market Timing
MarketTrendSignal.com
TrendsUniversity.com
MuscleStocks.com
![]()
![]()



